Thalidomide

• 

  Subject Areas on Research

  • A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. 
  • A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). 
  • Apremilast for the off-label treatment of lichenoid and interface dermatoses. 
  • Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. 
  • Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma. 
  • Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. 
  • Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. 
  • Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. 
  • Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide. 
  • Critical role of TNF-α in cerebral aneurysm formation and progression to rupture. 
  • Designs for randomized phase II clinical trials with two treatment arms. 
  • Does thalidomide affect IL-2 response and production? 
  • Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry. 
  • Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. 
  • Initial testing of lenalidomide by the pediatric preclinical testing program. 
  • Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. 
  • Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. 
  • Lenalidomide after stem-cell transplantation for multiple myeloma. 
  • Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus. 
  • Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. 
  • Multiple myeloma, version 1.2013. 
  • Myelodysplastic syndromes. 
  • Non-Hodgkin's lymphomas, version 1.2013. 
  • Novel antiangiogenic therapies for renal cell cancer. 
  • Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. 
  • Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma. 
  • Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. 
  • Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. 
  • Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. 
  • Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). 
  • Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. 
  • Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. 
  • Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. 
  • Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). 
  • Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. 
  • Successful management of refractory pediatric-onset complex aphthosis with lenalidomide. 
  • TNF-α/TNFR1 Signaling is Required for the Full Expression of Acute and Chronic Itch in Mice via Peripheral and Central Mechanisms. 
  • Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. 
  • Thalidomide as salvage therapy for chronic graft-versus-host disease. 
  • Thalidomide for recalcitrant nodular scleritis in sarcoidosis. 
  • Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. 
  • Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. 
  • The Need for Pediatric Drug Development. 
  • The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. 
  • The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. 
  • The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. 
  • Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). 
  • Update on new immunomodulatory agents. 
  • Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. 
  • Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma. 
  • β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression.